BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 18807178)

  • 1. Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients.
    Rao NY; Hu Z; Yu JM; Li WF; Zhang B; Su FX; Wu J; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 Aug; 116(3):563-70. PubMed ID: 18807178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Assessing BRCA carrier probabilities in extended families.
    Barcenas CH; Hosain GM; Arun B; Zong J; Zhou X; Chen J; Cortada JM; Mills GB; Tomlinson GE; Miller AR; Strong LC; Amos CI
    J Clin Oncol; 2006 Jan; 24(3):354-60. PubMed ID: 16421416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of BRCA1 and BRCA2 mutation carrier prediction models in breast and/or ovarian cancer families of French Canadian descent.
    Oros KK; Ghadirian P; Maugard CM; Perret C; Paredes Y; Mes-Masson AM; Foulkes WD; Provencher D; Tonin PN
    Clin Genet; 2006 Oct; 70(4):320-9. PubMed ID: 16965326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRCA1 and BRCA2 genetic testing in Hispanic patients: mutation prevalence and evaluation of the BRCAPRO risk assessment model.
    Vogel KJ; Atchley DP; Erlichman J; Broglio KR; Ready KJ; Valero V; Amos CI; Hortobagyi GN; Lu KH; Arun B
    J Clin Oncol; 2007 Oct; 25(29):4635-41. PubMed ID: 17925560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the pedigree assessment tool (PAT) in families with BRCA1 and BRCA2 mutations.
    Teller P; Hoskins KF; Zwaagstra A; Stanislaw C; Iyengar R; Green VL; Gabram SG
    Ann Surg Oncol; 2010 Jan; 17(1):240-6. PubMed ID: 19763692
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal selection of individuals for BRCA mutation testing: a comparison of available methods.
    James PA; Doherty R; Harris M; Mukesh BN; Milner A; Young MA; Scott C
    J Clin Oncol; 2006 Feb; 24(4):707-15. PubMed ID: 16446345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of mathematical models for breast cancer risk assessment in routine clinical use.
    Fasching PA; Bani MR; Nestle-Krämling C; Goecke TO; Niederacher D; Beckmann MW; Lux MP
    Eur J Cancer Prev; 2007 Jun; 16(3):216-24. PubMed ID: 17415092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving the accuracy of BRCA1/2 mutation prediction: validation of the novel country-customized IC software.
    Capalbo C; Ricevuto E; Vestri A; Sidoni T; Buffone A; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Eur J Hum Genet; 2006 Jan; 14(1):49-54. PubMed ID: 16288312
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A probability model for predicting BRCA1 and BRCA2 mutations in breast and breast-ovarian cancer families.
    Vahteristo P; Eerola H; Tamminen A; Blomqvist C; Nevanlinna H
    Br J Cancer; 2001 Mar; 84(5):704-8. PubMed ID: 11237395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of models to predict BRCA germline mutations.
    Kang HH; Williams R; Leary J; ; Ringland C; Kirk J; Ward R
    Br J Cancer; 2006 Oct; 95(7):914-20. PubMed ID: 17016486
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretest prediction of BRCA1 or BRCA2 mutation by risk counselors and the computer model BRCAPRO.
    Euhus DM; Smith KC; Robinson L; Stucky A; Olopade OI; Cummings S; Garber JE; Chittenden A; Mills GB; Rieger P; Esserman L; Crawford B; Hughes KS; Roche CA; Ganz PA; Seldon J; Fabian CJ; Klemp J; Tomlinson G
    J Natl Cancer Inst; 2002 Jun; 94(11):844-51. PubMed ID: 12048272
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal selection for BRCA1 and BRCA2 mutation testing using a combination of 'easy to apply' probability models.
    Bodmer D; Ligtenberg MJ; van der Hout AH; Gloudemans S; Ansink K; Oosterwijk JC; Hoogerbrugge N
    Br J Cancer; 2006 Sep; 95(6):757-62. PubMed ID: 16909138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating breast cancer risk: available models to assess individual breast cancer risk and probability to be a BRCA mutation carrier.
    Pasini B; Casalis Cavalchini GC; Genovese T; Manoukian S
    J Exp Clin Cancer Res; 2002 Sep; 21(3 Suppl):23-9. PubMed ID: 12585650
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation predictions using the BRCAPRO and Myriad models in Korean ovarian cancer patients.
    Eoh KJ; Park JS; Park HS; Lee ST; Han J; Lee JY; Kim SW; Kim S; Kim YT; Nam EJ
    Gynecol Oncol; 2017 Apr; 145(1):137-141. PubMed ID: 28159408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening.
    Hoskins KF; Zwaagstra A; Ranz M
    Cancer; 2006 Oct; 107(8):1769-76. PubMed ID: 16967460
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
    Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does the search for large genomic rearrangements impact BRCAPRO carrier prediction?
    Capalbo C; Buffone A; Vestri A; Ricevuto E; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    J Clin Oncol; 2007 Jun; 25(18):2632-4; author reply 2634-5. PubMed ID: 17577048
    [No Abstract]   [Full Text] [Related]  

  • 19. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
    Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
    Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Accuracy of BRCA1/2 mutation prediction models in Korean breast cancer patients.
    Kang E; Park SK; Yang JJ; Park B; Lee MH; Lee JW; Suh YJ; Lee JE; Kim HA; Oh SJ; Kim SW;
    Breast Cancer Res Treat; 2012 Aug; 134(3):1189-97. PubMed ID: 22438049
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.